Edgewise’s sevasemten sale boosted bottom line by $1.4B
Edgewise Therapeutics Inc. received nearly $1.4 billion in upfront cash proceeds during the third quarter as a result of the sale of its muscular-dystrophy business to French pharmaceutical company Les Laboratoires Servier.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Tampa-based Lazydays Holdings Inc. says it expects its sale of the Lazydays of Denver at…
-
DigitalOcean Holdings Inc. (NYSE: DOCN) plans to sell nearly 10.4 million new shares of common…
-
What will be the future of Naropa University, the iconic, Buddhism-inspired liberal-arts school after the…
-
Noodles & Co. (Nasdaq: NDLS) informed regulators and investors this week that the Broomfield fast-casual…
